Insider Selling: Avalyn Pharma (NASDAQ:AVLN) Insider Sells $5,087,250.00 in Stock

Avalyn Pharma Inc. (NASDAQ:AVLN) insider Fmr Llc sold 175,000 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $29.07, for a total transaction of $5,087,250.00. Following the transaction, the insider directly owned 2,109,535 shares in the company, valued at approximately $61,324,182.45. This trade represents a 7.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Fmr Llc also recently made the following trade(s):

• On Tuesday, November 10th, Fmr Llc sold 53,454 shares of Avalyn Pharma stock. The shares were sold at an average price of $30.21, for a total value of $1,614,845.34.

Avalyn Pharma Trading Down 3.6%

Shares of AVLN traded down $1.13 during mid-day trading on Thursday, hitting $30.49. The company’s stock had a trading volume of 185,254 shares, compared to its average volume of 338,945. The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average price of $28.87. Avalyn Pharma Inc. has a 52-week low of $22.24 and a 52-week high of $40.17. The company has a market cap of $1.35 billion and a price-to-earnings ratio of -1.34.

Avalyn Pharma (NASDAQ:AVLN) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.03). As a group, sell-side analysts predict that Avalyn Pharma Inc. will post -3.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Avalyn Pharma

Large investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of Avalyn Pharma during the third quarter valued at approximately $29,000. Manchester Capital Management LLC acquired a new stake in shares of Avalyn Pharma in the third quarter worth approximately $36,000. Profund Advisors LLC acquired a new stake in shares of Avalyn Pharma in the third quarter worth approximately $668,000. Bank of New York Mellon Corp purchased a new stake in shares of Avalyn Pharma during the second quarter worth approximately $1,321,000. Finally, State Street Corp purchased a new stake in shares of Avalyn Pharma during the second quarter worth approximately $10,501,000.

Analyst Upgrades and Downgrades

Several brokerages recently commented on AVLN. Raymond James Financial began coverage on shares of Avalyn Pharma in a report on Friday, October 2nd. They issued an “outperform” rating and a $60.00 price target for the company. Morgan Stanley increased their price objective on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Wall Street Zen lowered shares of Avalyn Pharma from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Avalyn Pharma in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $60.00.

Avalyn Pharma Company Profile

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.